1. Home
  2. LPCN vs GRNQ Comparison

LPCN vs GRNQ Comparison

Compare LPCN & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPCN
  • GRNQ
  • Stock Information
  • Founded
  • LPCN 1997
  • GRNQ 2013
  • Country
  • LPCN United States
  • GRNQ Malaysia
  • Employees
  • LPCN N/A
  • GRNQ N/A
  • Industry
  • LPCN Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • LPCN Health Care
  • GRNQ Technology
  • Exchange
  • LPCN Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • LPCN 16.1M
  • GRNQ 12.8M
  • IPO Year
  • LPCN N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • LPCN $3.00
  • GRNQ $2.12
  • Analyst Decision
  • LPCN Strong Buy
  • GRNQ
  • Analyst Count
  • LPCN 2
  • GRNQ 0
  • Target Price
  • LPCN $9.00
  • GRNQ N/A
  • AVG Volume (30 Days)
  • LPCN 29.3K
  • GRNQ 84.5K
  • Earning Date
  • LPCN 08-07-2025
  • GRNQ 08-12-2025
  • Dividend Yield
  • LPCN N/A
  • GRNQ N/A
  • EPS Growth
  • LPCN N/A
  • GRNQ N/A
  • EPS
  • LPCN N/A
  • GRNQ N/A
  • Revenue
  • LPCN $3,674,834.00
  • GRNQ $3,190,761.00
  • Revenue This Year
  • LPCN N/A
  • GRNQ N/A
  • Revenue Next Year
  • LPCN N/A
  • GRNQ N/A
  • P/E Ratio
  • LPCN N/A
  • GRNQ N/A
  • Revenue Growth
  • LPCN N/A
  • GRNQ N/A
  • 52 Week Low
  • LPCN $2.68
  • GRNQ $0.80
  • 52 Week High
  • LPCN $7.61
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • LPCN 40.07
  • GRNQ 65.90
  • Support Level
  • LPCN $3.10
  • GRNQ $1.78
  • Resistance Level
  • LPCN $3.39
  • GRNQ $2.50
  • Average True Range (ATR)
  • LPCN 0.18
  • GRNQ 0.18
  • MACD
  • LPCN -0.00
  • GRNQ 0.04
  • Stochastic Oscillator
  • LPCN 0.00
  • GRNQ 63.11

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: